<ul>
	<li>Serious Infections- do not administer tocilizumab during an active infection, including localized infections. If a serious infection develops, interrupt tocilizumab until the infection is controlled.</li>
	<li>Gastrointestinal (GI) perforation- use with caution in patients who may be at increased risk.</li>
	<li>Hepatotoxicity- Monitor patients for signs and symptoms of hepatic injury. Modify or discontinue tocilizumab if abnormal liver tests persist or worsen or if clinical signs and symptoms of liver disease develop.</li>
	<li>Laboratory monitoring- recommended due to potential consequences of treatment-related changes in neutrophils, platelets, lipids, and liver function tests.</li>
	<li>Hypersensitivity reactions, including anaphylaxis and death have occurred.</li>
	<li>Live vaccines- Avoid use with tocilizumab.</li>
</ul>